Six peptides were recommended. One was not. The margins were narrow throughout, and the one rejection came down to a single vote.
The votes themselves are the most informative thing to come out of the July 2026 PCAC meeting, because they show a committee that was genuinely divided — and that disagreed with the FDA's own scientific staff on nearly every question in front of it.
The tally, in full
| Peptide | Yes | No | Abstain | Outcome |
|---|---|---|---|---|
| BPC-157 | 8 | 6 | 1 | Recommended |
| KPV | 8 | 6 | 1 | Recommended |
| TB-500 | 8 | 6 | 1 | Recommended |
| Semax | 8 | 5 | 1 | Recommended |
| MOTS-c | 7 | 5 | 2 | Recommended |
| Epitalon | 7 | 4 | 1 | Recommended |
| Emideltide (DSIP) | 6 | 7 | 1 | Not recommended |
Not one of these was a landslide. The widest margin was three votes. Emideltide lost by one.
What the spread tells you
A committee that splits 8–6 on the strongest candidate is not a committee that found the evidence compelling. It is a committee that found the evidence sufficient — which is a much lower bar, and the correct bar for the question it was actually asked.
The question on the table was not “does this work”
This is where most commentary goes wrong. Committee members were not asked to decide whether BPC-157 heals tendons or whether Epitalon extends lifespan. They were asked whether each substance is appropriate for inclusion on a list of bulk drug substances that licensed pharmacies may use in patient-specific compounded preparations.
That determination turns on three narrower questions: whether the substance can be adequately characterized for identity, purity and potency; whether it presents significant safety risks when compounded; and whether enough published literature exists to inform safe compounding practice.
A member could vote yes while privately believing a compound does very little. A member could vote no while believing it works, if the characterization data looked weak. Reading these votes as verdicts on efficacy is a category error.
FDA scientists said no to all seven
In every single case, agency scientists presented and recommended against inclusion. Their objections were consistent across the two days: insufficient safety information, insufficient efficacy information, and inadequate characterization of the molecules.
The committee went the other way six times.
That is the structural story of this meeting. An advisory panel does not usually overrule the review staff of the agency it advises, let alone repeatedly. The FDA now holds a set of recommendations its own scientists argued against, and has to decide what weight to give each.
Context on committee composition
In late June 2026, STAT News reported that the FDA had named eight new members to the PCAC, and that a majority of them were connected to businesses that promote or prescribe peptides. The reporting raised conflict-of-interest questions ahead of the vote. We cover the composition question separately; it is relevant background for reading a 6–1 outcome that ran against staff recommendations, and it is a fair thing for readers to weigh for themselves.
Why emideltide fell short
Emideltide — delta sleep-inducing peptide, universally called DSIP — was reviewed for opioid withdrawal, chronic insomnia and narcolepsy. It lost 6 to 7, with one abstention.
Committee members who voted against it pointed to evidence quality as the deciding factor. That framing is worth sitting with, because DSIP was not obviously worse-supported than several compounds that passed. What distinguished it was the breadth of what was being asked.
The indication-scope problem
Look at what each compound was evaluated for:
- TB-500 — wound healing. One mechanism, one endpoint.
- Epitalon — insomnia. Narrow, and measurable.
- BPC-157 — ulcerative colitis. Specific disease, specific tissue.
- Emideltide — opioid withdrawal, chronic insomnia and narcolepsy.
DSIP came in carrying three indications spanning addiction medicine and two distinct sleep disorders. Each would require its own evidence base. A committee already stretching to find sufficiency in thin literature had three times as much ground to cover, and the literature did not extend that far.
The lesson generalizes: narrowly-scoped nominations fared better than broadly-scoped ones, independent of how much anyone believed in the underlying molecule.
What each compound was actually reviewed for
Worth restating, because the gap between the reviewed indication and the marketed use is wide for most of these:
| Peptide | Indication FDA reviewed | What it's typically marketed for |
|---|---|---|
| BPC-157 | Ulcerative colitis | Tendon, ligament and joint repair |
| TB-500 | Wound healing | Athletic recovery, injury repair |
| KPV | Wound healing, inflammatory conditions | Gut health, skin inflammation |
| MOTS-c | Obesity, osteoporosis | Metabolic optimization, longevity |
| Epitalon | Insomnia | Telomere length, anti-aging |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Cognitive enhancement, focus |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | Sleep quality, stress |
The right-hand column has essentially no regulatory standing. If a rule is eventually written, it will be written around the left-hand column.
The conditional votes
Several members who voted yes attached conditions — requirements around authorized API sourcing, adverse-event reporting, and permitted formulations. Those conditions are not binding on the FDA, but they signal what a workable rule might have to include, and they suggest even supportive members were uneasy about the current supply landscape.
That is a meaningful tell. The people who voted to expand access mostly did so on the theory that regulated access beats unregulated access — not on the theory that these compounds are well understood.
What to take from the numbers
Four conclusions
- Every vote was close. This was a divided panel, not a mandate.
- FDA staff opposed all seven nominations; the committee overrode them six times.
- Emideltide's rejection tracks its unusually broad indication scope, not obviously weaker science.
- The reviewed indications differ sharply from the marketed ones for nearly every compound.
Common questions
Emideltide/DSIP, at 6 in favor and 7 against with one abstention. A single vote the other way would have produced a clean seven-for-seven outcome.
Agency reviewers cited three recurring problems: insufficient safety data, insufficient efficacy data, and inadequate characterization of the molecules themselves. Characterization — being able to say reliably what is in a given batch — came up repeatedly and is arguably the central technical objection.
Procedurally, no. A majority is a majority and the recommendation carries forward as advice to the agency. Practically, a divided panel that overrode its own staff gives the FDA more room to take its time or to impose conditions in any eventual rule.
Nothing prevents a future nomination. There is no announced plan to revisit it, and it is not on the agenda for the meeting scheduled before the end of February 2027.
No. The committee assessed whether each substance could be adequately characterized and handled safely in a compounding pharmacy, and whether enough literature exists to guide that work. That is a question about pharmacy practice, not a clinical safety finding for patients.
Sources
- US Food and Drug Administration. “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Docket FDA-2026-N-2979. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” Client alert, July 27, 2026.
- Holland & Knight. “FDA Advisory Committee Endorses Compounding of Certain Peptides.” August 2026.
- Latham & Watkins. “FDA on Peptides: A New Landscape for Compounders.” 2026.
- Buchanan Ingersoll & Rooney PC. “FDA PCAC Recommends Six Peptides for the 503A Bulks List.” 2026.
- Sheppard Mullin. “What to Watch: Status Update on Peptide Regulation.” June 2026.
- STAT News. Reporting on new PCAC panelist appointments, June 29, 2026.